Cargando…

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

PURPOSE OF REVIEW: We highlight the unique properties of the sodium-glucose cotransporter-2 (SGLT-2 inhibitors) which may lend favorably to their efficient integration in the background of other heart failure (HF) therapies. We also discuss the unique aspects of SGLT-2 inhibitor dosing, lack of titr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Muhammad Shahzeb, Vaduganathan, Muthiah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Macrovascular Complications in Diabetes (VR Aroda and L-S Chang, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548057/ https://www.ncbi.nlm.nih.gov/pubmed/33040170 http://dx.doi.org/10.1007/s11892-020-01347-3

Ejemplares similares

Do Women with Diabetes Need More Intensive Action for Cardiovascular Reduction than Men with Diabetes?
por: Harreiter, Jürgen, et al.
Publicado: (2020)

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Wang, Xiaowen, et al.
Publicado: (2020)

Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events?
por: Gourgari, Evgenia, et al.
Publicado: (2017)

Cardiovascular and Mortality Risks in Migrant South Asians with Type 2 Diabetes: Are We Winning the Battle?
por: Johns, Emma, et al.
Publicado: (2017)

Revisiting the Diabetes-Heart Failure Connection
por: Wallner, Markus, et al.
Publicado: (2018)

Effect of Health Information Technologies on Cardiovascular Risk Factors among Patients with Diabetes
por: Yoshida, Yilin, et al.
Publicado: (2019)

Regulating Polyamine Metabolism by miRNAs in Diabetic Cardiomyopathy
por: Kambis, Tyler N., et al.
Publicado: (2021)

Thinking Ahead to the Next Generation of Cardiometabolic Investigators: What It Takes to Successfully Engage Underrepresented Minorities in Biomedical and Public Health Careers
por: White, Wendy B., et al.
Publicado: (2022)

COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study
por: Smati, Sarra, et al.
Publicado: (2022)

Social Determinants of Health, Race, and Diabetes Population Health Improvement: Black/African Americans as a Population Exemplar
por: Hill-Briggs, Felicia, et al.
Publicado: (2022)

Genetics of Type 2 Diabetes: Implications from Large-Scale Studies
por: DeForest, Natalie, et al.
Publicado: (2022)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
por: Aggarwal, Rahul, et al.
Publicado: (2021)

Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes
por: Wretlind, Asger, et al.
Publicado: (2023)

High Connectivity Between Reduced Cortical Thickness and Disrupted White Matter Tracts in Long-Standing Type 1 Diabetes
por: Franc, Daniel T., et al.
Publicado: (2011)

Cause-Specific Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes
por: Secrest, Aaron M., et al.
Publicado: (2010)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Partial Inhibition of Insulin Secretion Results in Glucose Intolerance but Not Hyperglucagonemia
por: Ramanathan, Ranjani P., et al.
Publicado: (2011)

Association of Organochlorine Pesticides with Peripheral Neuropathy in Patients with Diabetes or Impaired Fasting Glucose
por: Lee, Duk-Hee, et al.
Publicado: (2008)

High Glucose Induces Toll-Like Receptor Expression in Human Monocytes: Mechanism of Activation
por: Dasu, Mohan R., et al.
Publicado: (2008)

Glucagon Supports Postabsorptive Plasma Glucose Concentrations in Humans With Biologically Optimal Insulin Levels
por: Cooperberg, Benjamin A., et al.
Publicado: (2010)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
por: Neumiller, Joshua J, et al.
Publicado: (2022)

The Medial Amygdalar Nucleus: A Novel Glucose-Sensing Region That Modulates the Counterregulatory Response to Hypoglycemia
por: Zhou, Ligang, et al.
Publicado: (2010)

Slowing of Peripheral Nerve Conduction Velocity in Children and Adolescents With Type 1 Diabetes Is Predicted by Glucose Fluctuations
por: Oberhauser, Sarah S., et al.
Publicado: (2023)

The Rate of Fall of Blood Glucose Determines the Necessity of Forebrain-Projecting Catecholaminergic Neurons for Male Rat Sympathoadrenal Responses
por: Jokiaho, Anne J., et al.
Publicado: (2014)

In Vivo Insulin Sensitivity and Secretion in Obese Youth: What are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes?
por: Bacha, Fida, et al.
Publicado: (2009)

Sirtuin 1–Mediated Cellular Metabolic Memory of High Glucose Via the LKB1/AMPK/ROS Pathway and Therapeutic Effects of Metformin
por: Zheng, Zhi, et al.
Publicado: (2012)

Relationship of Glycated Albumin to Blood Glucose and HbA(1c) Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study
por: Nathan, David M., et al.
Publicado: (2014)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023)

Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions
por: Laursen, Jens Christian, et al.
Publicado: (2021)

IDF2022-0971 Comparison of severity of COVID amongst patients with newly detected diabetes vs. patients with pre-existing diabetes
por: Maheshwari, A., et al.
Publicado: (2023)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Could virtual reality applications pose real risks to children and adolescents? A systematic review of ethical issues and concerns
por: Kaimara, Polyxeni, et al.
Publicado: (2021)

Virtual reality as a communication medium: a comparative study of forced compliance in virtual reality versus physical world
por: Dzardanova, Elena, et al.
Publicado: (2021)

Burden of Urological Complications in Men and Women With Long-standing Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort
por: Wessells, Hunter, et al.
Publicado: (2018)

A role of the adaptive immune system in glucose homeostasis
por: Bronsart, Laura L, et al.
Publicado: (2016)

Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease
por: Sesti, Giorgio, et al.
Publicado: (2014)

Genetic variation in sodium glucose co‐transporter 1 and cardiac structure and function at middle age
por: Bavishi, Aakash, et al.
Publicado: (2022)

Glucose Effectiveness in Obese Children: Relation to Degree of Obesity and Dysglycemia
por: Weiss, Ram, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jp9r3mf4665fspvi3vl672hcu8